# A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC

> clinical trial · VERIFIED · 2026-06-26

Status: COMPLETED · Sponsor: Zhejiang Cancer Hospital · Condition: Extensive-stage Small-cell Lung Cancer

- Company: Zhejiang Cancer Hospital
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06478043

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.